Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1117

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1117
---
 former through direct experimental screening, and the latter through
machine-learning based prediction based on chemical structure.

BioSymetrics intends to expand the use of its platform
across the biopharmaceutical and healthcare markets. The company is developing its technology in compliance with applicable healthcare
data privacy regulations, including HIPAA and GDPR, and is focused on building AI solutions that address the growing demand for robust,
transparent, and reliable applications of artificial intelligence in life sciences.

Our Intellectual Property

Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions, and improvements to inventions that we consider
important for the development of our business. We rely on a combination of patent, copyright, trademark, and trade secret laws, as well
as continuing technological innovations, proprietary knowledge, and various third-party agreements, including, without limitation, confidentiality
agreements, materials transfer agreements, research agreements, and licensing agreements, to establish and protect our proprietary rights.
We aim to take advantage of all of the intellectual property rights that are available to us and seek the protection of those rights so
that we can fully exploit our innovations.

We also protect our proprietary
information by requiring our employees, consultants, contractors, and other advisors to execute nondisclosure and assignment of invention
agreements upon commencement of their respective employment or engagement.

Assigned Intellectual Property

On August 16, 2022, the USPTO
issued U.S. Patent No. 11,413,338 B2, “Methods and Compositions Using Recombinant Dendritic Cells for Cancer Therapy”, pertaining
to methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous
proteins. This patent protects RENB-DC11: Genetically modified Allogeneic Dendritic Cells as Potential Product for Long-term
Remission of Solid Tumors – Starting with Pancreatic Cancer and potential future products RENB-DC-12XX: Genetically
modified Allogeneic Dendritic Cells as Potential Product for Long-term Remission of Additional Indications for twenty years. The Company
owns this patent application, through assignment as of July 15, 2019.

On July 5, 2022, the USPTO issued
Patent No. US-11379757-B2, “Methods, systems, and frameworks for data analytics using machine learning”, pertaining to methods
for pre-processing multi-modal data for biomedical applications.